However, a recent meta-analysis illustrated that clinical use of TZT for 1 year in the management of obesity and glucose control was superior compared to semaglutide, dulaglutide, degludec, and insulin (Dutta et al. 2021). This evidence concerns the gene INS and obesity disorder.